Answers are grounded in this paper and cite their sources.
Review highlights evidence-based strategies for anticoagulation timing and duration in venous thromboembolism, suggesting tailored management to balance efficacy and bleeding.
Venous thromboembolism (VTE) is a prevalent medical condition with high morbidity, mortality, and associated costs. Anticoagulation remains the main treatment for VTE, though the decision on when, how, and for how long to administer anticoagulants is increasingly complex. This review highlights the different phases of VTE management, with special circumstances for consideration such as antiphospholipid syndrome, coronary artery disease, cancer-associated thrombus, COVID-19, and future anticoagulation options. Anticoagulation management will continue to be a complex decision, applying evidence-based medicine to individual patients with the hope of maximizing effectiveness while minimizing risks.
No takes yet. Share an insight, caveat, or question.
Malik et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: